There's nothing like free publicity to help goose the sales of a relatively new product. Cancer-diagnostics specialist Guardant Health (GH 5.87%) was a standout in the biotech sector on Hump Day. Investors cheered the company's news that one of its products made it onto a list of top innovations compiled by a familiar magazine. In response, they traded Guardant's shares up by almost 6%, making it quite the outperformer when matched against the S&P 500 index's 0.3% drop on the day. One of the top innovations ...

Guardant Health (GH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Nove ...

Guardant Health needs cash. Until it can get it from selling enough services, it must sell its own shares instead. Shares of precision medicine company Guardant Health (GH -11.13%), which specializes in liquid biopsies to test for cancer, fell 10.6% through 10:05 a.m. ET Monday morning. Monday was the first trading day in which investors got to react to a Guardant announcement late Friday, that it plans to sell stock and raise $400 million in new cash to fund its operations. Guardant needs money Guardant's ...

After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages. The 20-day moving ...

| --- | --- | --- | |----------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Transforming Cancer Care Q2 2024 Earnings Call August 7, 2024 | | | Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve know ...

Guardant Health, Inc. (NASDAQ:GH) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Daniel Brennan - TD Cowen Puneet Souda - Leerink Partners Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Jack Meehan - Nephron Research ...

Guardant Health (GH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.67 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 15.79%. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.72 per share when it actually produced a loss of $0.46, delivering a surprise of 36.11%. Over the last four quart ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specifi ...

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC screening and is commercially available in U.S. PALO ALTO, Calif. August 7, 2024 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlight ...

Wall Street analysts forecast that Guardant Health (GH) will report quarterly loss of $0.57 per share in its upcoming release, pointing to a year-over-year increase of 14.9%. It is anticipated that revenues will amount to $161.93 million, exhibiting an increase of 18.1% compared to the year-ago quarter. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial p ...